TY - JOUR
T1 - Pseudohypoparathyroidism, acrodysostosis, progressive osseous heteroplasia
T2 - different names for the same spectrum of diseases?
AU - Elli, Francesca Marta
AU - Mantovani, Giovanna
N1 - Funding Information:
Open access funding provided by Universit? degli Studi di Milano within the CRUI-CARE Agreement.
Funding Information:
Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.
Publisher Copyright:
© 2020, The Author(s).
PY - 2021/6
Y1 - 2021/6
N2 - Pseudohypoparathyroidism (PHP), the first known post-receptorial hormone resistance, derives from a partial deficiency of the α subunit of the stimulatory G protein (Gsα), a key component of the PTH/PTHrP signaling pathway. Since its first description, different studies unveiled, beside the molecular basis for PHP, the existence of different subtypes and of diseases in differential diagnosis associated with genetic alterations in other genes of the PTH/PTHrP pathway. The clinical and molecular overlap among PHP subtypes and with different but related disorders make both differential diagnosis and genetic counseling challenging. Recently, a proposal to group all these conditions under the novel term “inactivating PTH/PTHrP signaling disorders (iPPSD)” was promoted and, soon afterwards, the first international consensus statement on the diagnosis and management of these disorders has been published. This review will focus on the major and minor features characterizing PHP/iPPSDs as a group and on the specificities as well as the overlap associated with the most frequent subtypes.
AB - Pseudohypoparathyroidism (PHP), the first known post-receptorial hormone resistance, derives from a partial deficiency of the α subunit of the stimulatory G protein (Gsα), a key component of the PTH/PTHrP signaling pathway. Since its first description, different studies unveiled, beside the molecular basis for PHP, the existence of different subtypes and of diseases in differential diagnosis associated with genetic alterations in other genes of the PTH/PTHrP pathway. The clinical and molecular overlap among PHP subtypes and with different but related disorders make both differential diagnosis and genetic counseling challenging. Recently, a proposal to group all these conditions under the novel term “inactivating PTH/PTHrP signaling disorders (iPPSD)” was promoted and, soon afterwards, the first international consensus statement on the diagnosis and management of these disorders has been published. This review will focus on the major and minor features characterizing PHP/iPPSDs as a group and on the specificities as well as the overlap associated with the most frequent subtypes.
UR - http://www.scopus.com/inward/record.url?scp=85095805017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095805017&partnerID=8YFLogxK
U2 - 10.1007/s12020-020-02533-9
DO - 10.1007/s12020-020-02533-9
M3 - Review article
C2 - 33179219
AN - SCOPUS:85095805017
SN - 1355-008X
VL - 72
SP - 611
EP - 618
JO - Endocrine
JF - Endocrine
IS - 3
ER -